AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial
The trial will enrol up to 30 PAH and ten ILD-PH class II and III patients for ROC-101 combination therapy.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance